生物治疗用丁酸梭菌 MIYAIRI 588 菌株可增强 Rorγt+Treg 的肠动力和 PD-1 阻断疗效

IF 12.2 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Gut Microbes Pub Date : 2024-02-22 DOI:10.1080/19490976.2024.2315631

Thomas Paz Del Socorro, Kentaro Oka, Olivier Boulard, Motomichi Takahashi, Lionel Franz Poulin, Atsushi Hayashi, Mathias Chamaillard

引用次数: 0

摘要

免疫检查点抑制剂（ICI）已被定位为晚期非小细胞肺癌（NSCLC）患者的标准治疗方法。一项试点临床试验显示，免疫检查点抑制剂对晚期非小细胞肺癌（NSCLC）患者的疗效令人乐观。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The biotherapeutic Clostridium butyricum MIYAIRI 588 strain potentiates enterotropism of Rorγt+Treg and PD-1 blockade efficacy

Immune checkpoint inhibitors (ICI) have been positioned as a standard of care for patients with advanced non-small-cell lung carcinomas (NSCLC). A pilot clinical trial has reflected optimistic asso...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Gut Microbes Medicine-Microbiology (medical)

CiteScore

18.20

自引率

3.30%

发文量

196

审稿时长

10 weeks

期刊介绍： The intestinal microbiota plays a crucial role in human physiology, influencing various aspects of health and disease such as nutrition, obesity, brain function, allergic responses, immunity, inflammatory bowel disease, irritable bowel syndrome, cancer development, cardiac disease, liver disease, and more. Gut Microbes serves as a platform for showcasing and discussing state-of-the-art research related to the microorganisms present in the intestine. The journal emphasizes mechanistic and cause-and-effect studies. Additionally, it has a counterpart, Gut Microbes Reports, which places a greater focus on emerging topics and comparative and incremental studies.